Plasma α1-antitrypsin: A Neglected Predictor of Angiographic Severity in Patients with Stable Angina Pectoris

Hui Zhao, Hong Liu, Lin Chai, Ping Xu, Lu Hua, Xiao-Yuan Guan, Bing Duan, Yi-Ling Huang, Yi-Shi Li
Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China

Background: As an acute phase protein, α1-antitrypsin (AAT) has been extensively studied in acute coronary syndrome, but it is unclear whether a relationship exists between AAT and stable angina pectoris (SAP). The purpose of the present study was to investigate the association between AAT plasma levels and SAP.

Methods: Overall, 103 SAP patients diagnosed by coronary angiography and clinical manifestations and 118 control subjects matched for age and gender were enrolled in this case-control study. Plasma levels of AAT, high-sensitivity C-reactive protein (hsCRP), lipid profiles and other clinical parameters were assayed for all participants. The severity of coronary lesions was evaluated based on the Gensini score (GS) assessed by coronary angiography.

Results: Positively correlated with the GS (r = 0.564, P < 0.001), the plasma AAT level in the SAP group was significantly higher than that in the control group (142.08 ± 19.61 mg/dl vs. 125.50 ± 19.67 mg/dl, P < 0.001). The plasma AAT level was an independent predictor for both SAP (odds ratio [OR] = 1.037, 95% confidence interval [CI]: 1.020–1.054, P < 0.001) and a high GS (OR = 1.087, 95% CI: 1.051–1.124, P < 0.001) in a multivariate logistic regression model. In the receiver operating characteristic curve analysis, plasma AAT level was found to have a larger area under the curve (AUC) for predicting a high GS (AUC = 0.858, 95% CI: 0.788–0.929, P < 0.001) than that of hsCRP (AUC = 0.665, 95% CI: 0.557–0.773, P = 0.006; Z = 2.9363, P < 0.001), with an optimal cut-off value of 137.85 mg/dl (sensitivity: 94.3%, specificity: 68.2%).

Conclusions: Plasma AAT levels correlate with both the presence and severity of coronary stenosis in patients with SAP, suggesting that it could be a potential predictive marker of severe stenosis in SAP patients.

Key words: α1-antitrypsin; Angiography; Coronary Artery Disease; Gensini Score; Inflammation; Stable Angina Pectoris

INTRODUCTION

Stable angina pectoris (SAP) is one of the most common subtypes of coronary artery disease (CAD), affecting approximately 54 million patients worldwide. An individual’s prognosis can vary considerably from chronic recurrent angina pectoris to acute myocardial infarction (AMI). Early and accurate identification of SAP patients with high risk is of great clinical value. α1-antitrypsin (AAT) is an acute phase protein that is mainly produced in the liver. An elevated plasma AAT level has been widely confirmed in the setting of AMI and acute coronary syndrome (ACS); however, data regarding this marker in SAP patients are limited. Recently, a study using proteomic techniques found that AAT was differentially expressed in atherosclerotic plaques, indicating its role in the long-term progression of atherosclerosis. However, previous studies on the relationship between plasma AAT concentrations and the severity of CAD are insufficient. A higher plasma AAT level was observed in patients with higher Gensini scores (GSs) who did not have AMI, which implies an association between plasma AAT levels and coronary stenosis. However, few receiver operating characteristic (ROC) curve analyses of plasma AAT concentration for predicting CAD severity have been performed. Moreover, plasma AAT levels correlate with both the presence and severity of coronary stenosis in patients with SAP, suggesting that it could be a potential predictive marker of severe stenosis in SAP patients.
AAT concentration is likely to be different in patients with SAP and unstable angina pectoris (UAP) because of their differing pathological features. Thus, it is unclear whether plasma AAT is an independent predictor for the severity of coronary atherosclerosis in SAP patients.

Accordingly, we proposed that elevated plasma AAT levels in SAP patients could be a valuable predictor for the risk and severity of the disease. To test this hypothesis, plasma AAT levels were first compared between SAP patients and controls. We also investigated the diagnostic value of this marker in the identification of SAP patients with severe coronary lesions.

**Methods**

**Study population**

We consecutively recruited 103 CAD patients with SAP at Fuwai Hospital from July to October 2012 for this study. SAP was defined as chest pain typical of cardiac ischemia on exertion or emotional stress that is relieved by rest or nitrates. The pattern of chest pain did not change within at least 1 month. All patients had undergone coronary angiography and had angiographically documented narrowing of at least 50% of the luminal diameter of a major coronary artery. Subjects with AMI, heart failure (left ventricular ejection fraction <30%), cardiomyopathies, and valvular disease were excluded. Also from July to October 2012, a total of 118 age- and gender-matched controls without CAD were enrolled. They were determined to be free of CAD by a history lacking angina and other heart diseases, a normal electrocardiogram (ECG) and normal results of exercise ECG stress testing. The exclusion criteria for both groups were as follows: Acute or chronic infection, definite inflammatory and immune-associated diseases, bleeding, surgery or trauma within 12 weeks prior to admission, liver or renal dysfunction and neoplasms. Patients were also excluded if they had been taking statin drugs or any anti-inflammatory medications. The study protocol complied with the Declaration of Helsinki and was approved by the ethics committee of Fuwai Hospital. All of the participants provided written informed consent.

All participants received a standard medical history, physical examination and laboratory assessment. The participants were diagnosed with hypertension if their systolic blood pressure was ≥140 mmHg and/or their diastolic blood pressure was ≥90 mmHg; hypertension was also diagnosed by self-report of a physician diagnosis, and if any anti-hypertensive treatment was taken at admission. Diabetes mellitus (DM) was diagnosed according to the standards of the American Diabetes Association, which include a fasting plasma glucose level ≥7.0 mmol/L, a 2-h postload glucose level ≥11.1 mmol/L, self-report of a physician diagnosis, and if any hypoglycemic medication taken at admission. Smokers were defined as those who regularly smoked five cigarettes or more a day, and if patients had stopped smoking for more than 10 years preceding disease onset, they were classified as nonsmokers. In addition, body mass index (BMI) was calculated as weight (kg)/height² (m²).

**Coronary angiography**

Selective coronary angiography was performed using a standard Judkins technique. CAD was defined as the presence of obstructive stenosis in any of the main coronary arteries, including the left main coronary artery (LM), left anterior descending artery (LAD), left circumflex coronary artery (LCX) and right coronary artery, and any of the main branches of the vascular system of more than 50% of the lumen diameter. The severity of coronary lesions was assessed by the GS,[9] which was calculated according to the severity of stenosis as follows: 1 point for <25% stenosis, 2 points for 26%–50% stenosis, 4 points for 51%–75% stenosis, 8 points for 76%–90% stenosis and 32 points for complete occlusion. The score was then multiplied by a coefficient representing the importance of the lesion’s position in the coronary artery system. For example, coefficients of 5 for the LM, 2.5 for the proximal region of the LAD and LCX, 1.5 for the middle region, and 1 for the distal region of the LAD and mid-distal region of the LCX. All results were analyzed by at least two experienced interventional physicians from the cardiology department of Fuwai Hospital, who performed a quantitative coronary angiography analysis and were blind to the objective of the study.

Stable angina pectoris patients enrolled in this study were further divided into three subgroups based on the tertile of the GS (low GS <18 points, n = 34; intermediate GS 18–40 points, n = 34; high GS >40 points, n = 35).

**Laboratory tests**

Venous blood was drawn from all individuals after a 12 h overnight fast prior to coronary angiography and was centrifuged immediately at 3000 r/min and 4°C for 10 min. Plasma specimens were then collected and stored at −80°C until further analysis. All specimens were analyzed at the same time to control for testing variability. Plasma AAT and high-sensitivity C-reactive protein (hsCRP) levels were measured by immunoturbidimetry[10] using an IMMAGE 800 immunochemistry system (Beckman Coulter, USA). The AAT reagent (447740, Beckman Coulter, USA) and hsCRP reagent (474630, Beckman Coulter, USA) were used according to the manufacturer’s instructions. Total cholesterol and triglycerides were assayed by routine enzymatic methods (GPO-PAP) using a Beckman DxC800 analyzer (Fullerton, USA). High-density lipoprotein cholesterol (HDL-C) level was measured using a chemical modification and selective melting kit (Kyowa Medex, Tokyo, Japan). The low-density lipoprotein cholesterol (LDL-C) concentration was calculated using the Friedewald equation.[11] The intra- and inter-assay coefficients of variation for plasma AAT level ranged from 2.1% to 3.1%, and 2.8% to 3.3%, respectively. The AAT level reference range was 88–174 mg/dl.

**Statistical analysis**

All statistical analyses were performed using the SPSS 17.0 software package (SPSS Inc., Chicago, IL, USA). The Kolmogorov–Smirnov test was used to determine
the data distribution patterns. Continuous variables are presented as the means ± SD or medians with the 25th and 75th percentiles, as appropriate. Variables with a skewed distribution were log-transformed for further statistical testing. Differences between groups were compared using the t-test or one-way ANOVA. Categorical variables are expressed as frequencies or percentages, and differences were compared with the Chi-square test or Fisher’s exact test. Pearson and Spearman correlation coefficients were used to evaluate the correlations between AAT plasma concentration and other variables when appropriate. Subsequently, multiple linear regression analysis was performed to investigate a set of independent risk factors associated with plasma AAT level. Spearman correlation analysis was also used to determine the correlations between plasma AAT levels and GSs in SAP patients. The predictive values of different clinical variables for the SAP risk and a high GS (>40) were determined using the univariate and multivariate logistic regression model. ROC curves were generated to assess the diagnostic value of plasma AAT for SAP and a high GS. The maximum Youden index was used to determine the optimal cut-off values. The diagnostic values of plasma AAT and hsCRP were compared using Z test. A P < 0.05 was considered to indicate a statistically significant difference.

**RESULTS**

**Baseline clinical characteristics of the study population**

To investigate the relationship between plasma AAT level and SAP, 221 subjects were enrolled in the present study, including 103 SAP patients and 118 non-CAD controls. Because the inflammation-modulating capacity of statins has been confirmed, patients with statin treatment were excluded from our study as previously described. Thus, data regarding the effects of statin use are not presented. The baseline clinical characteristics and biochemical parameters of the study population are summarized in Table 1. Age, gender, BMI, smoking status and the presence of diabetes showed no significant difference between the SAP group and the control group. There were more hypertensive patients in the SAP group than in the control group. As expected, patients in the SAP group had significantly higher mean levels of plasma hsCRP, AAT and LDL-C and a lower mean HDL-C level compared with the control group.

**Plasma α1-antitrypsin concentration assessment**

The plasma AAT concentrations for all subjects ranged from 81.15 to 188.10 mg/dl with a median of 133.23 mg/dl. In the total population studied, the plasma AAT concentration was positively correlated with age, smoking status and the plasma hsCRP level, and negatively correlated with the plasma HDL-C level [Table 2]. In covariance analysis, adjusted plasma AAT concentration controlling for these possible confounding factors was still higher in the SAP group.

---

### Table 1: Baseline characteristics of the study population

| Variables                  | Control group (n = 118) | SAP group (n = 103) | P   |
|----------------------------|-------------------------|---------------------|-----|
| Demographic data           |                         |                     |     |
| Male, n (%)                | 79 (66.9)               | 73 (70.9)           | 0.563 |
| Age (years)                | 54.62 ± 8.35            | 53.01 ± 8.75        | 0.164 |
| BMI (kg/m²)                | 25.92 ± 3.37            | 26.36 ± 3.74        | 0.360 |
| Diabetes, n (%)            | 18 (15.3)               | 23 (22.3)           | 0.225 |
| Hypertension, n (%)        | 55 (46.6)               | 73 (70.9)           | <0.001 |
| Smoking, n (%)             | 53 (44.9)               | 49 (47.6)           | 0.787 |
| Biochemical parameters     |                         |                     |     |
| TC, mmol/L                 | 4.47 ± 0.70             | 4.52 ± 0.89         | 0.639 |
| TG, mmol/L                 | 1.71 ± 0.99             | 1.78 ± 0.99         | 0.615 |
| HDL-C, mmol/L              | 1.18 ± 0.29             | 1.06 ± 0.32         | 0.005 |
| LDL-C, mmol/L              | 2.60 ± 0.60             | 2.85 ± 0.76         | 0.006 |
| hsCRP, mg/L                | 1.08 (0.62–1.76)        | 2.02 (1.07–3.38)    | <0.001 |
| AAT, mg/dl                 | 125.50 ± 19.67          | 142.08 ± 19.61      | <0.001 |
| Medications, n (%)         |                         |                     |     |
| Statins                    | –                       | –                   | –   |
| Aspirin                    | 11 (9.3)                | 15 (14.6)           | 0.296 |
| CCB                        | 20 (16.9)               | 20 (19.4)           | 0.727 |
| ACEI/ARB                   | 13 (11.0)               | 20 (19.4)           | 0.254 |
| Beta blocker               | 27 (22.9)               | 37 (35.9)           | 0.123 |

SAP: Stable angina pectoris; BMI: Body mass index; TC: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; hsCRP: High-sensitivity C-reactive protein; AAT: α1-antitrypsin; CCB: Calcium channel blocker; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin-receptor blocker; P: P value for SAP group versus control group.

### Table 2: Correlations between plasma AAT concentration and other variables

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | r                   | P                     | B (95% CI) | P   |
| Male                       | 0.068               | 0.317                 | –         | –   |
| Age                        | 0.182               | 0.007                 | 0.493     | 0.171–0.815 | 0.003 |
| BMI                        | 0.669               | 0.504                 | –         | –   |
| Diabetes                   | 0.049               | 0.469                 | –         | –   |
| Hypertension               | 0.145               | 0.031                 | 1.324     | −4.391–7.038 | 0.648 |
| Smoking                    | 0.153               | 0.023                 | 6.238     | 0.721–11.756 | 0.027 |
| TC                         | −0.028              | 0.690                 | –         | –   |
| TG                         | −0.108              | 0.114                 | –         | –   |
| HDL-C                      | −0.184              | 0.006                 | −9.701    | −18.953–0.449 | 0.040 |
| LDL-C                      | 0.121               | 0.072                 | –         | –   |
| hsCRP                      | 0.297               | <0.001                | 10.691    | 5.021–16.362 | <0.001 |
| Aspirin                    | 0.109               | 0.105                 | –         | –   |
| CCB                        | 0.008               | 0.902                 | –         | –   |
| ACEI/ARB                   | 0.039               | 0.569                 | –         | –   |
| Beta blocker               | 0.129               | 0.056                 | –         | –   |

BMI: Body mass index; TC: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; hsCRP: High-sensitivity C-reactive protein; CCB: Calcium channel blocker; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin-receptor blocker; AAT: α1-antitrypsin.
group than that in the controls \((141.17 \pm 21.82 \text{ mg/dl} \text{ vs. } 126.28 \pm 19.88 \text{ mg/dl}, P < 0.001)\).

**Correlations between plasma \(\alpha_1\)-antitrypsin concentration and stable angina pectoris**

To confirm the predictive value of an increased plasma AAT level for SAP, univariate and multivariate logistic regression analyses were performed. As shown in Table 3, plasma levels of LDL-C, hsCRP and AAT were found to be independent predictors of SAP (LDL-C: Odds ratio \((OR) = 1.724, 95\% \text{ confidence interval (CI)}: 1.100–2.702, P = 0.017; \text{hsCRP}: \text{OR} = 2.908, 95\% \text{ CI} = 1.402–6.033, P = 0.004; \text{AAT}: \text{OR} = 1.037, 95\% \text{ CI} = 1.020–1.054, P < 0.001). To test the diagnostic value of plasma AAT concentration for SAP, ROC curves were established. As shown in Figure 1a, plasma AAT levels were comparable to hsCRP levels for distinguishing patients with SAP from controls (AAT: Area under the curve (AUC) = 0.721, 95\% CI: 0.655–0.788, \(P < 0.001\); hsCRP: AUC = 0.698, 95\% CI: 0.628–0.768, \(P < 0.001\); \(Z = 0.45817, P = 0.105\)). The plasma AAT concentration was of certain value in predicting SAP with a sensitivity of 63.4\% and a specificity of 67.8\%. The best cut-off value calculated using the Youden index was 133.72 mg/dl.

**Correlations between plasma \(\alpha_1\)-antitrypsin concentration and coronary Gensini score**

Gensini score was used to assess the severity of coronary atherosclerotic lesions. SAP patients were divided into three subgroups according to their angiographic results. The baseline characteristics of these subgroups are presented in Table 4. Patients with a high GS had higher plasma AAT levels, whereas those with a low GS had the lowest AAT levels (low GS subgroup <18: 130.17 ± 15.83 mg/dl; intermediate GS subgroup 18–40: 137.94 ± 17.73 mg/dl; high GS subgroup >40: 157.68 ± 13.98 mg/dl).

To further investigate the association between plasma AAT concentrations and coronary severity, a Spearman analysis was performed. As shown in Figure 2, there was a significant positive correlation between plasma AAT levels and GS in patients with SAP \((n = 103, r = 0.564, P < 0.001)\).

**Table 3: Univariate and multivariate logistic regression analysis of risk factors and laboratory parameters to identify independent predictors of SAP**

| Variables | \(OR\) | 95\% CI | \(P\) |
|-----------|--------|---------|------|
| **Univariate analysis** | | | |
| Male | 1.201 | 0.678–2.130 | 0.530 |
| Age | 0.978 | 0.948–1.009 | 0.164 |
| BMI | 1.036 | 0.961–1.117 | 0.356 |
| Diabetes | 1.597 | 0.807–3.163 | 0.179 |
| Hypertension | 2.787 | 1.595–4.870 | <0.001 |
| Smoking | 1.113 | 0.655–1.891 | 0.693 |
| TC | 1.089 | 0.771–1.540 | 0.628 |
| TG | 1.073 | 0.817–1.408 | 0.613 |
| HDL-C | 0.256 | 0.097–0.677 | 0.006 |
| LDL-C | 1.742 | 1.161–2.615 | 0.007 |
| hsCRP | 4.395 | 2.194–8.806 | <0.001 |
| AAT | 1.044 | 1.028–1.060 | <0.001 |
| Aspirin | 1.658 | 0.725–3.793 | 0.231 |
| CCB | 1.181 | 0.595–2.343 | 0.635 |
| ACEI/ARB | 1.946 | 0.915–4.142 | 0.084 |
| Beta blocker | 1.889 | 1.049–3.404 | 0.034 |
| **Multivariate analysis** | | | |
| LDL-C | 1.724 | 1.100–2.702 | 0.017 |
| hsCRP | 2.908 | 1.402–6.033 | 0.004 |
| AAT | 1.037 | 1.020–1.054 | <0.001 |

BMI: Body mass index; TC: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; hsCRP: High-sensitivity C-reactive protein; AAT: \(\alpha_1\)-antitrypsin; CCB: Calcium channel blocker; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin-receptor blocker; \(OR\): Odds ratio; CI: Confidence interval; SAP: Stable angina pectoris.

**Figure 1:** ROC curve analyses of the predictive power of plasma AAT level. (a) ROC curve analysis for SAP diagnosis; (b) ROC curve analysis for a high GS (\(>40\)) identification. hsCRP: High-sensitivity C-reactive protein; AAT: \(\alpha_1\)-antitrypsin; AUC: Area under the curve; CI: Confidence interval; SAP: Stable angina pectoris; GS: Gensini score; ROC: Receiver operating characteristic.
Additionally, we performed the univariate analysis between the SAP patients with high GS (>40) and those with low and moderate GS (1–40). The data showed that patients with high GS (>40) were more frequently older and had significantly elevated plasma AAT and hsCRP levels. Moreover, the multivariate logistic regression analysis showed that only the plasma AAT level was identified as an independent predictor of a high GS in SAP patients (OR = 1.087, 95% CI: 1.051–1.124, \(P < 0.001\)), which suggests a more severe atherosclerotic lesion.

Finally, the ROC curve analysis [Figure 1b] showed a moderate diagnostic value of plasma AAT levels for identifying SAP patients with high GS from those with low and moderate GS (AUC = 0.858, 95% CI: 0.788–0.929, \(P < 0.001\)), and it was better than that of plasma hsCRP levels (AUC = 0.665, 95% CI: 0.557–0.773, \(P = 0.006\); \(Z = 2.9363, P < 0.001\)). Additionally, we found that a plasma AAT level of 137.85 mg/dl was an effective cut-off point for differentiating SAP patients with severe atherosclerotic lesions from those without, with a sensitivity of 94.3% and a specificity of 68.2%.

**DISCUSSION**

Our study demonstrated that plasma AAT levels were significantly higher in patients with SAP than in controls. An elevated plasma AAT level was found to be an independent risk factor for both the presence of SAP and a high GS. The ROC curve analysis indicated that plasma AAT level could be a potential marker of the presence and severity of SAP. In particular, a plasma AAT level of 137.85 mg/dl or higher identified SAP patients with high GSs with a sensitivity of 94.3% and a specificity of 68.2%. All of these findings suggest that plasma AAT levels could serve as a valuable predictor in the screening of SAP patients for more severe coronary stenosis, and these patients would greatly benefit from further examination and treatment, such as percutaneous coronary intervention and stenting.

\(\alpha_1\)-antitrypsin is an acute phase protein. The elevation of its plasma level has been well documented in the setting of ACS. In 1983, Gilutz et al. first confirmed an elevated plasma AAT

![Figure 2: Correlations between the plasma AAT level and the Gensini score in the SAP patients. There was a significantly positive correlation between the plasma AAT level and the Gensini score in SAP patients (\(r = 0.564, P < 0.001\)). AAT: \(\alpha_1\)-antitrypsin; SAP: Stable angina pectoris.](image)

| Variables                                | Low GS (<18, \(n = 34\)) | Intermediate GS (18–40, \(n = 34\)) | High GS (>40, \(n = 35\)) | \(P\)   |
|------------------------------------------|---------------------------|-------------------------------------|---------------------------|--------|
| Demographic data                         |                           |                                     |                           |        |
| Male, \(n\) (%)                          | 21 (61.8)                 | 23 (67.6)                           | 29 (82.9%)                | 0.129  |
| Age (years)                              | 52.21 ± 7.36              | 51.06 ± 8.76                        | 55.69 ± 9.53              | 0.071  |
| BMI (kg/m\(^2\))                         | 25.48 ± 3.55              | 27.05 ± 4.22                        | 26.54 ± 3.33              | 0.214  |
| Diabetes, \(n\) (%)                      | 6 (17.6)                  | 9 (26.5)                            | 8 (22.9)                  | 0.699  |
| Hypertension, \(n\) (%)                  | 23 (67.6)                 | 25 (73.5)                           | 25 (71.4)                 | 0.893  |
| Smoking, \(n\) (%)                       | 14 (41.2)                 | 17 (50.0)                           | 18 (51.4)                 | 0.684  |
| Biochemical parameters                   |                           |                                     |                           |        |
| TC (mmol/L)                              | 4.54 ± 0.85               | 4.42 ± 0.91                         | 4.60 ± 0.91               | 0.692  |
| TG (mmol/L)                              | 1.91 ± 1.17               | 1.67 ± 0.90                         | 1.75 ± 0.91               | 0.612  |
| HDL-C (mmol/L)                           | 1.06 ± 0.32               | 1.09 ± 0.32                         | 1.02 ± 0.33               | 0.640  |
| LDL-C (mmol/L)                           | 2.73 ± 0.83               | 2.80 ± 0.70                         | 3.03 ± 0.75               | 0.238  |
| hsCRP (mg/L)                             | 1.83 (0.96–3.62)          | 1.71 (0.85–2.77)                    | 2.66 (1.67–3.55)          | 0.013  |
| AAT (mg/dl)                              | 130.17 ± 15.83            | 137.94 ± 17.73                      | 157.68 ± 13.98            | <0.001 |
| Medications, \(n\) (%)                   |                           |                                     |                           |        |
| Statins                                  | –                         |                                     | –                         |        |
| Aspirin                                  | 6 (17.6)                  | 3 (8.8)                             | 6 (17.1)                  | 0.605  |
| CCB                                      | 6 (17.6)                  | 6 (17.6)                            | 8 (22.9)                  | 0.860  |
| ACEI/ARB                                 | 7 (20.6)                  | 6 (17.6)                            | 7 (20)                    | 0.948  |
| Beta blocker                             | 14 (41.2)                 | 10 (29.4)                           | 13 (37.1)                 | 0.619  |

GS: Gensini score; BMI: Body mass index; TC: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; hsCRP: High-sensitivity C-reactive protein; AAT: \(\alpha_1\)-antitrypsin; CCB: Calcium channel blocker; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin-receptor blocker.
level in patients with AMI. Later, Brunetti et al. reported an elevated plasma AAT level in patients with UAP. Therefore, AAT is considered a marker of ACS. However, different release curves of plasma AAT recently observed in patients with ST-segment elevation myocardial infarction (STEMI), non-STEMI and UAP indicate an association of the plasma AAT level with different pathological features of atherosclerosis. However, it was previously unclear whether AAT plasma level differs in patients with SAP. The present study is the first to confirm a significantly higher plasma AAT level in SAP patients compared with controls, suggesting that AAT is not only a marker of ACS, but is also involved in the chronic progression of atherosclerosis.

α1-antitrypsin is an acute phase protein; thus, its plasma level increases rapidly during inflammation due to the stimulation of its over-production by multiple cytokines. CAD is an inflammation-mediated atherosclerotic disease. Multiple inflammatory cells and mediators have been reported to help sustain and amplify pro-inflammatory signals, leading to the onset and development of atherosclerosis. Therefore, we supposed that the elevation of plasma AAT levels in SAP patients could be the result of the chronic inflammatory status of the disease. This was supported by the positive correlation between plasma hsCRP and AAT levels observed in the total population of our study. In addition to inflammation, plasma AAT levels were also found to be positively correlated with age and smoking status, and negatively correlated with HDL-C plasma levels, and these results were similar to those of previous large-scale population-based studies. Old age, smoking, and low plasma HDL-C level were all related to high plasma AAT levels, and after adjusting for these possible confounders, the plasma AAT level was still associated with SAP. The ROC curve analysis further demonstrated that plasma AAT level was an independent predictor of SAP.

Gensini score has been used to evaluate the severity of CAD. Mori et al. observed the plasma AAT level in “chest discomfort” patients without AMI and found a higher plasma AAT level in those patients with a higher GS, implying a possible association of AAT and coronary lesions. However, whether plasma AAT is a predictive factor of the severity of coronary stenosis was not previously analyzed further. In our study, a positive correlation between plasma AAT levels and GS was confirmed in patients with SAP. After adjusting for other risk factors, plasma AAT levels were still related to a high GS, indicating that the plasma AAT concentration is an independent risk factor for the severity of SAP. In addition, the ROC curve analysis showed that plasma AAT levels could effectively identify SAP patients with severe coronary stenosis from those with low and moderate GS. Increasing evidence has demonstrated that the presence of AAT in atherosclerotic plaques could enhance fibrosis due to its inhibitory effects on collagenase and elastase, and also suppress the infiltration of inflammatory cells into the arterial walls, and both of these factors are related to the progression of atherosclerosis and the loss of luminal diameter. All of these findings support the significant association between plasma AAT levels and coronary GS observed in our study.

As a well-known acute phase protein in cardiovascular diseases, hsCRP has been confirmed to be a diagnostic factor for CAD and to be associated with coronary angiographic severity. Our data showed that plasma AAT levels had a similar diagnostic value to that of hsCRP levels for SAP. However, the plasma AAT level was more powerful than the hsCRP level for identifying SAP patients with a higher GS. Interestingly, plasma AAT levels were better at distinguishing high GS-patients from low and moderate GS-patients than at distinguishing SAP patients from controls. This suggests that measurement of plasma AAT has more value for recognizing severe coronary stenosis in patients with suspected CAD in clinical practice. As there is a need to reduce health care costs, and the risk of cardiovascular events in SAP patients with severe coronary stenosis, plasma AAT levels may be a useful screening tool for clinicians. Therefore, SAP patients with a significantly increased plasma AAT levels are more inclined to receive further evaluation by coronary angiography. In our study, the severity of coronary stenosis was only evaluated by GS. The association of plaque vulnerability and AAT requires further study with intravascular ultrasound and optical coherence tomography. Because of the strong correlation between AAT levels and GS, future studies should evaluate plasma AAT levels in asymptomatic CAD patients.

There are several limitations to our study. First, our sample size was small, and our subjects were obtained from a single center. The diagnostic value of plasma AAT level needs to be further evaluated in a large study population with standardized diagnostic tests. Second, cardiovascular events were not analyzed in this study due to its cross-sectional design, and the value of plasma AAT levels in prognosis prediction must be assessed during patient follow-up.

In conclusion, our study demonstrated a significantly higher plasma AAT level in patients with SAP compared to controls. Plasma AAT levels were an independent risk factor of SAP and a higher GS. Plasma AAT concentrations could be measured in SAP patients to predict the severity of coronary lesions.

Acknowledgments

We thank the doctors and nurses from Fujui Hospital who offered help in plasma specimen collection and clinical data collection. We thank Prof. Wei-Jiang Hu who offered help in statistics process.

References

1. Siásos G, Tousoulis D, Athanasiou D, Oikonomou E, Tourikis P, Gouliopoulos N, et al. Novel risk factors related to stable angina. Curr Pharm Des 2013;19:1559-61.
2. Hong LF, Li XL, Luo SH, Guo YL, Zhu CG, Qing P, et al. Association of fibrinogen with severity of stable coronary artery disease in patients with type 2 diabetic mellitus. Dis Markers 2014;2014:485687.
3. Drakopoulou M, Toutouzas K, Stefanadi E, Tsiamis E, Tousoulis D, Stefanadis C. Association of inflammatory markers with angiographic severity and extent of coronary artery disease. Atherosclerosis 2009;206:335-9.

4. Brunetti ND, Correale M, Pellegrino PL, Cuculo A, Biase MD. Acute phase proteins in patients with acute coronary syndrome: Correlations with diagnosis, clinical features, and angiographic findings. Eur J Intern Med 2007;18:109-17.

5. Glitzenstein H, Siegel Y, Paran E, Cristal N, Quastel MR. Alpha-l-antitrypsin in acute myocardial infarction. Br Heart J 1983;49:26-9.

6. Ziakas AG, Koskinas KC, Souliou E, Gavriliadis S, Giannouli GD, Gemitzis K, et al. Serial measurements of acute phase proteins in patients with acute coronary syndrome. Hellenic J Cardiol 2011;52:293-8.

7. Donners MM, Verluyten MJ, Bouwman FG, Mariman EC, Devreese B, Vantrobaeys F, et al. Proteomic analysis of differential protein expression in human atherosclerotic plaque progression. J Pathol 2005;206:39-45.

8. Mori T, Sasaki J, Kawaguchi H, Handa K, Takada Y, Matsunaga A, et al. Serum glycoproteins and severity of coronary atherosclerosis. Am Heart J 1995;129:234-8.

9. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983;51:606.

10. Fellah H, Omar S, Feki M, Abderrahim E, Ben Abdallah T, Massy ZA, et al. Serum transthyretin as a reliable marker of nutritional status in patients with end-stage renal disease? Clin Biochem 2008;41:493-7.

11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.

12. van ‘t Wout EF, van Schadewijk A, Savage ND, Stolk J, Hiemstra PS. A1-antitrypsin production by proinflammatory and antiinflammatory macrophages and dendritic cells. Am J Respir Cell Mol Biol 2012;46:607-13.

13. Bosco D, Meda P, Morel P, Matthey-Doret D, Caille D, Tosco C, et al. Expression and secretion of alpha-1-proteinase inhibitor are regulated by proinflammatory cytokines in human pancreatic islet cells. Diabetologia 2005;48:1523-33.

14. Morgan K, Marsters P, Morley S, van Gent D, Hejazi A, Backx M, et al. Oncostatin M induced alpha-antitrypsin (AAT) gene expression in Hep G2 cells is mediated by a 3’ enhancer. Biochem J 2002;365:555-60.

15. Weissberg PL, Bennett MR. Atherosclerosis – An inflammatory disease. N Engl J Med 1999;340:1928-9.

16. Linja-aho A, Mazur W, Toljamo T, Nieminen P, Ohlmeier S, Rönty M, et al. Distribution and levels of alpha-1-antitrypsin in the lung and plasma in smokers and chronic obstructive pulmonary disease. APMIS 2013;121:11-21.

17. Al-Bayaty FH, Baharuddin N, Abdulla MA, Ali HM, Arkilla MB, AIBayaty MF. The influence of cigarette smoking on gingival bleeding and serum concentrations of haptoglobin and alpha-l-antitrypsin. Biomed Res Int 2013;2013:684154.

18. Serapinas D, Narbekovas A, Juškevičius J, Sakalauskas R. Systemic inflammation in COPD in relation to smoking status. Multidiscip Respir Med 2011;6:214-9.

19. Senn O, Russi EW, Schindler C, Imboden M, von Eckardstein A, Brändli O, et al. Circulating alpha-1-antitrypsin in the general population: Determinants and association with lung function. Respir Res 2008;9:35.

20. Leblig J, Reibetanz U, Schönberg M, Neundorf I. Efficient inhibition of human leukocytic elastase by means of α1-antitrypsin/peptide complexes. Cytometry A 2013;83:461-71.

21. Jonigk D, Al-Omari M, Maegel L, Müller M, Izyskowski N, Hong J, et al. Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase. Proc Natl Acad Sci U S A 2013;110:15007-12.

22. Pott GB, Chan ED, Dinarello CA, Shapiro L. Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol 2009;85:886-95.

23. Churg A, Wang X, Wang RD, Meixner SC, Pryzdial EL, Wright JL. Alpha-1-antitrypsin suppresses TNF-alpha and MMP-12 production by cigarette smoke-stimulated macrophages. Am J Respir Cell Mol Biol 2007;37:144-51.

24. Chan ED, Pott GB, Silkoff PE, Ralston AH, Bryan CL, Shapiro L. Alpha-1-antitrypsin inhibits nitric oxide production. J Leukoc Biol 2012;92:1251-60.

25. Fang Z, Zhou L, Bao Y, Ding W, Shi H, Luo X, et al. Association of NT-proBNP and multiple biomarkers with severity of angiographic coronary artery disease in diabetic and pre-diabetic Chinese patients. PLoS One 2011;6:e22563.